The evaluation of oxidative stress parameters in the benign prostatic hyperplasia, prostatitis and prostate cancer

Yıl 2019, , 315 - 321, 01.09.2019

Aliseydi Bozkurt , Cebrail Gürsul Merve Aydin İlyas Sayar Mehmet Karabakan Aytekin Çikman

https://doi.org/10.21601/ortadogutipdergisi.462457

Cited By: 1

Öz

Aim: Recently, oxidative stress has been well known that it has especially important a role in benign prostatic hyperplasia, prostatitis, and prostate cancer. The present study has planned to estimate parameters of the oxidative stress and the antioxidant status in patients with benign prostatic hyperplasia, prostatitis and prostate cancer.
Material and Method: For this aim totally fourty men with benign prostatic hyperplasia (n=14), prostatitis (n=15) and prostate cancer (n=11) without any other chronic disease, and who not use cigarettes and alcohol were subjected. Venous blood samples were taken. Thiobarbituric acid reaction (TBARS), total oxidant status (TOS), total antioxidant capacity (TAC), glutathione (GSH) levels, and catalase (CAT) activity in serum were assessed in patient with prostatitis, and prostate cancer compared to benign prostatic hyperplasia.
Results: It was viewed that GSH levels were significantly lower, TBARS and TOS levels were significantly higher in patients with of prostate cancer compared to benign prostatic hyperplasia. Also, GSH and CAT significant different was determined in prostatitis compared to BPH. Oxidative stress may be concluded in prostate cancer and prostatitis, proved via the higher TBARS levels and lower GSH levels.
Conclusion: The increased activity of antioxidant enzyme may be a compensatory regulation in response to oxidative stress.

Anahtar Kelimeler

benign prostatic hyperplasia, prostatitis, prostate cancer, oxidative stress

Benign prostat hiperplazisi, prostatit ve prostat kanserinde oksidatif stres parametrelerinin değerlendirilmesi

Öz

Amaç: Son zamanlarda, oksidatif stresin iyi huylu prostat hiperplazisi, prostatit ve prostat kanserinde özellikle önemli bir rolü olduğu iyi bilinmektedir. Bu çalışma benign prostat hiperplazisi, prostatit ve prostat kanseri olan hastalarda oksidatif stres ve antioksidan parametreleri değerlendirmeyi planlamaktadır.
Gereç ve Yöntem: Bu amaçla benign prostat hiperplazisi (n = 14), prostatit (n = 15) ve prostat kanseri (n=11) diğer kronik hastalığı olmayan, sigara ve alkol kullanmayan toplamda kırk erkek hasta değerlendirmeye alındı. Venöz kan örnekleri alındı. Prostatit ve prostat kanserli hastalarda tirobarbitürik asit reaksiyonu (TBARS), total oksidan durum (TOS), total antioksidan kapasite (TAC), glutatyon (GSH) düzeyleri ve katalaz (CAT) aktivitesi iyi huylu prostat hiperplazisine göre değerlendirildi.
Bulgular: GSH düzeylerinin anlamlı derecede düşük olduğu, TBARS ve TOS düzeylerinin benign prostat hiperplazisine göre prostat kanserli hastalarda anlamlı olarak daha yüksek olduğu görülmüştür. Ayrıca, GSH ve CAT, BPH ile karşılaştırıldığında prostatitde önemli ölçüde farklı bulunmuştur. Oksidatif stres, daha yüksek TBARS seviyeleri ve daha düşük GSH seviyeleri ile prostat kanseri ve prostatit de görülebilir.
Sonuç: Antioksidan enzimin artan aktivitesi, oksidatif strese yanıt olarak telafi edici bir düzenleme olabilir.

Anahtar Kelimeler

benign prostat hiperplazisi, prostatit, prostat kanseri, oksidatif stres

Kaynakça

• (AUA) AUA. AUA guideline on management of benign prostatic hyperplasia. Diagnosis and treatment recommendations. AUA Practice Guidelines Committee. J Urol. 2003; 170: 530-47.
• Pagano E, Laudato M, Griffo M, Capasso R. Phytotherapy of Benign Prostatic Hyperplasia. A Minireview. Phytother Res. 2014; 28: 949-55.
• Murphy L, Watson RW. Patented prostate cancer biomarkers. Nat Rev Urol. 2012; 9: 464-72.
• Arsova-Sarafinovska Z, Eken A, Matevska N, et al. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem 2009; 42: 1228-35.
• Chomyn A, Attardi G. MtDNA mutations in aging and apoptosis. Biochem Bioph Res Co 2003; 304: 519-29.
• Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006; 59: 10-6.
• Motrich RD, Maccioni M, Molina R, et al. Presence of INF gamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol. 2005; 116: 149-57.
• Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2005; 26: 1170-81.
• Turk S, Kullisaar T. Are prostatitis symptoms associated with an isoprostane-mediated vicious circle? Med Hypotheses. 2011; 77: 837-40.
• Sciarra A, Di Silverio F, Salciccia S, Gomez AMA, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: Evidence for a link? Eur Urol. 2007; 52: 964-72.
• de Miguel MP, Royuela M, Bethencourt FR, Santamaria L, Fraile B, Paniagua R. Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate. Cytokine. 2000; 12: 535-8.
• Naka K, Muraguchi T, Hoshii T, Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Sign. 2008; 10: 1883-94.
• Kalra N, Prasad S, Shukla Y. Antioxidant potential of black tea against 7,12-dimethylbenz(a)anthracene-induced oxidative stress in Swiss albino mice. J Environ Pathol Tox. 2005; 24: 105-14.
• Damber JE, Aus G. Prostate cancer. Lancet. 2008; 371: 1710-21.
• Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology. 2011; 283: 65-87.
• Seifried HE, Anderson DE, Fisher EI, Milner JA. A review of the interaction among dietary antioxidants and reactive oxygen species. J Nutr Biochem. 2007; 18: 567-79.
• Elahi MM, Kong YX, Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev. 2009; 2: 259-69.
• Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscl Throm Vas. 2000; 20: 2175-83.
• Jung K, Seidel B, Rudolph B, et al. Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. Free Radical Bio Med. 1997; 23: 127-33.
• Murray GI, Taylor VE, Mckay JA, et al. The Immunohistochemical Localization of Drug-Metabolizing-Enzymes in Prostate-Cancer. J Pathol. 1995; 177: 147-52.
• Pasqualotto FF, Sharma RK, Potts JM, Nelson DR, Thomas AJ, Agarwal A. Seminal oxidative stress in patients with chronic prostatitis. Urology. 2000; 55: 881-5.
• Yamazaki H, Schneider E, Myers CE, Sinha BK. Oncogene Overexpression and De-Novo Drug-Resistance in Human Prostate-Cancer Cells. Bba-Mol Basis Dis. 1994; 1226: 89-96.
• Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC, Comm W. Transurethral prostatectomy: Immediate and postoperative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients. J Urology. 2002; 167: 5-9.
• Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc. 1999; 91: 159-64.
• Wilson MJ, Woodson M, Wiehr C, Reddy A, Sinha AA. Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat. Exp Mol Pathol. 2004; 77: 7-17.
• Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. Faseb J. 2003; 17: 1195-214.
• DeWeese TL, Hruszkewycz AW, Marnett LJ. Oxidative stress in chemoprevention trials. Urology 2001; 57: 137-40.
• Cooke MS, Evans MD, Herbert KE, Lunec J. Urinary 8-oxo-2 ‘-deoxyguanosine - Source, significance and supplements. Free Radical Res. 2000; 32: 381-97.
• Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues 2002; 13: 540-9.
• Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res 2004; 43: 200-27.
• Meagher EA, Fitzgerald GA. Indices of lipid peroxidation in vivo: Strengths and limitations. Free Radical Bio Med 2000; 28: 1745-50.
• Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004; 266: 37-56.
• Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem-Biol Interact 2006; 160: 1-40.
• Chiou CC, Chang PY, Chan EC, Wu TL, Tsao KC, Wu JT. Urinary 8-hydroxydeoxyguano sine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 2003; 334: 87-94.
• Foksinski M, Kotzbach R, Szymanski W, Olinski R. The level of typical biomarker of oxidative stress 8-hydroxy-2 ‘-deoxyguanosine is higher in uterine myomas than in control tissues and correlates with the size of the tumor. Free Radical Bio Med 2000; 29: 597-601.
• Poulsen HE, Prieme H, Loft S. Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev 1998; 7: 9-16.
• Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339: 1-9.
• Volchegorskiï IA, Tarasov NI, Seregin SP. The role of free-radical lipid oxidation in the pathogenesis of chronic prostatitis. Urologiiâ Nefrologiiâ 1997; 5: 24-5
• Conklin KA. Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 2000; 37: 1-18.
• Zhou JF, Xiao WQ, Zheng YC, Dong J, Zhang SM. Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis. Asian J Androl 2006; 8: 317-23.
• Lei YF, Ren XH, Chen JL, Liu D, Ruan JL. Protective effects of grape seed-derived procyanidin extract against carrageenan-induced abacterial prostatitis in rats. J Funct Foods 2014; 7: 416-24.
• De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol-Semin Ori 2007; 25: 398-400.
• Hallstrom TMKA, Laiho M. Genetic changes and DNA damage responses in the prostate. Prostate. 2008; 68: 902-18.
• Akinloye O, Adaramoye O, Kareem O. Changes in antioxidant status and lipid peroxidation in Nigerian patients with prostate carcinoma. Pol Arch Med Wewn 2009; 119: 526-31.
• Aydin A, Arsova-Sarafinovska Z, Sayal A, et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem 2006; 39: 176-9.
• Adedapo KS, Arinola OG, Shittu OB, Kareem OI, Okolo CA, Nwobi LN. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer. Niger J Clin Pract 2012; 15: 293-7.
• Barker AM, Oberley LW, Cohen MB. Expression of antioxidant enzymes in human prostate adenocarcinoma. Prostate Cancer P D. 1997; 32: 229-33.